Tuberculosis Infection - Pipeline Assessment and Market Forecasts to 2018

Tuberculosis Infection - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Tuberculosis Infection - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Tuberculosis (TB) infection market. The report identifies the key trends shaping and driving the market. It also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global TB infection sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The global TB infection market was worth $38.3m in 2010. The market is expected to decline at a Compound Annual Growth Rate (CAGR) of 4.5% during the next eight years to reach $26.6m by 2018. The TB drugs market has been well-served by antimycobacterial agents and antibiotics since the 1960s. Cure rates have been improved with the conventional Directly Observed Therapy (DOTS). Multi-Drug Resistant Tuberculosis (MDR-TB) was a consequence of patient non-compliance and the long duration of therapy. Companies are actively developing products for the prophylaxis and cure of TB with shorter treatment durations. Two not-for-profit organizations - TB Alliance and the Aeras Global TB Vaccine Foundation - partnered with pharmaceutical players to develop novel therapies and vaccines that can provide better patient compliance and prevention against TB. However, the global TB drugs market is heading towards a phase of decline as no launches are expected until 2018. Prevalent and reported TB cases have also reduced due to increased access to the DOTS and DOTS-PLUS programs in developed countries.

Scope

The report provides information on the key drivers and challenges of the tuberculosis infection market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) TB infection market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as vaccines, antimycobacterial agents, oxazolidinones, DNA-dependent RNA polymerase inhibitors, T-cells stimulators, synthetic fluoroquinolone antibacterial agents, immunosuppressants, mycolic acid biosynthesis inhibitors, nitroimidazo-oxazine anti-bacterial agents, mycobacterial ATP synthase inhibitors, DNA synthesis inhibitors, cell wall synthesis inhibitors, dipiperidine antibiotic, Translocase 1 (TL-1) inhibitors, lipid peroxidation inhibitors, proteasome inhibitors and non metabolized glucose analogue.
- Analysis of the current and future competition in the seven key countries’ TB infection markets. Key market players covered are ActivBiotics Pharma, Aeras Global TB Vaccine Foundation, Archivel Farma S.L., AstraZeneca PLC, Bayer, GlaxoSmithKline, Imaxio, Immunitor USA Inc., Novartis, Pfizer, Sanofi, Sequella, Inc., Tibotec BVBA (subsidiary of J&J).
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the TB infection therapeutics market.
- Analysis of key recent licensing and partnership agreements in the TB infection market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global TB infection market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global TB infection market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global TB infection market landscape? – Identify, understand and capitalize.

Keywords

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials SHOW LESS READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Tuberculosis - Introduction
2.1 Overview
2.2 Epidemiology
2.3 Etiology
2.4 Clinical Presentation and Symptoms
2.5 Prognosis
2.6 Diagnosis
2.6.1 Polymerase Chain Reaction (PCR) Tests
2.6.2 Chest X-Rays
2.6.3 Sputum Analysis (Smear and Culture)
2.7 Risk Factors
2.8 Pathophysiology
2.9 Treatment
2.10 GlobalData Pipeline Report Guidance
3 Tuberculosis Infection Market - Market Characterization
3.1 Tuberculosis Infection Market Size (2005-2010) - Global
3.2 Tuberculosis Infection Market Forecast (2010-2018) - Global
3.3 Tuberculosis Infection Market Size (2005-2010) - The US
3.4 Tuberculosis Infection Market Forecast (2010-2018) - The US
3.5 Tuberculosis Infection Market Size (2005-2010) - France
3.6 Tuberculosis Infection Market Forecast (2010-2018) - France
3.7 Tuberculosis Infection Market Size (2005-2010) - Germany
3.8 Tuberculosis Infection Market Forecast (2010-2018) - Germany
3.9 Tuberculosis Infection Market Size (2005-2010) - Italy
3.10 Tuberculosis Infection Market Forecast (2010-2018) - Italy
3.11 Tuberculosis Infection Market Size (2005-2010) - Spain
3.12 Tuberculosis Infection Market Forecast (2010-2018) - Spain
3.13 Tuberculosis Infection Market Size (2005-2010) - The UK
3.14 Tuberculosis Infection Market Forecast (2010-2018) - The UK
3.15 Tuberculosis Infection Market Size (2005-2010) - Japan
3.16 Tuberculosis Infection Market Forecast (2010-2018) - Japan
3.17 Drivers and Barriers for the Tuberculosis Infection Market
3.17.1 Drivers for the Tuberculosis Infection Market
3.17.2 Barriers for the Tuberculosis Infection Market
3.18 Opportunity and Unmet Need
3.19 Key Takeaway
4 Tuberculosis Infection Market - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Drugs in the Tuberculosis
4.3.1 Isoniazid (INH)
4.3.2 Rifampin (RIF)
4.3.3 Pyrazinamide (PZA)
4.3.4 Ethambutol (EMB)
4.3.5 Streptomycin (SM) and Other Aminoglycosides
4.3.6 Rifabutin
4.3.7 Capreomycin
4.4 Key Takeaway
5 Tuberculosis - Pipeline Assessment
5.1 Overview
5.1.1 Tuberculosis Infection Market - Phase III Clinical Pipeline
5.1.2 Tuberculosis Infection Market - Phase II Clinical Pipeline
5.1.3 Tuberculosis Infection Market - Phase I Clinical Pipeline
5.1.4 Tuberculosis Infection Market - Preclinical Phase Pipeline
5.1.5 Tuberculosis Infection Market - Discovery Pipeline
5.2 Tuberculosis Infection Market - Pipeline Assessment by Mechanism of Action
5.2.1 Technology Trends Analytic Framework
5.3 Tuberculosis Infection Market - Pipeline Assessment by Clinical Phase of Development
5.4 Tuberculosis Infection - Most Promising Drugs under Clinical Development
5.5 Most Promising Drugs/Vaccines Profile
5.5.1 Moxifloxacin (TB Alliance)
5.5.2 MVA85A/AERAS-485 (Oxford-Emergent Tuberculosis Consortium Ltd/Aeras)
5.5.3 AERAS-402/Crucell Ad35 (AERAS/Crucell)
5.5.4 TMC207 (Tibotec/TB Alliance)
5.5.5 GSK M72 (GlaxoSmithKline (GSK) Biologicals/Aeras)
5.5.6 PA-824 (Chiron/TB Alliance)
5.6 Key Takeaway
6 Tuberculosis - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country
6.2 Clinical Trials by Phase of Clinical Development
6.3 Clinical Trials by Trial Status
6.4 Prominent and Overall Sponsors
6.5 Brief Profiles of Top Companies Participating in Clinical Trials
7 Tuberculosis - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 Tuberculosis Infection Market - Future Players
8.1 Introduction
8.2 Bayer
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Business Overview
8.2.4 Tuberculosis Pipeline Portfolio
8.3 Sanofi
8.3.1 Overview
8.3.2 Financial performance
8.3.3 Business Description
8.3.4 Tuberculosis Pipeline Portfolio
8.4 Pfizer
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Business Description
8.4.4 Tuberculosis Pipeline Portfolio
8.5 Novartis
8.5.1 Overview
8.5.2 Business Description
8.5.3 Financial Performance
8.5.4 Tuberculosis Pipeline Portfolio
8.6 TB Alliance, the US
8.6.2 Tuberculosis Pipeline Portfolio
8.7 Aeras (Aeras Global TB Vaccine Foundation), the US
8.7.1 Overview
8.7.2 Tuberculosis Pipeline Portfolio
8.8 Crucell, the Netherlands
8.8.1 Overview
8.8.2 Tuberculosis Pipeline Portfolio
8.9 Tibotec BVBA, Belgium
8.9.1 Overview
8.9.2 Tuberculosis Pipeline Portfolio
9 Tuberculosis - Licensing Merger and Acquisition Deals
10 Tuberculosis Therapeutics - Appendix
10.1 Definitions
10.2 Acronyms
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Tuberculosis Infection Market, Global, Revenues ($m), 2005-2010
Table 2: Tuberculosis Infection Market, Global, Market Forecasts ($m), 2010-2018
Table 3: Tuberculosis Infection Market, The US, Revenue ($m), 2005-2010
Table 4: Tuberculosis Infection Market, The US, Market Forecasts ($m), 2010-2018
Table 5: Tuberculosis Infection Market, France, Revenue ($m), 2005-2010
Table 6: Tuberculosis Infection Market, France, Market Forecast ($m), 2010-2018
Table 7: Tuberculosis Infection Market, Germany, Revenue ($m), 2005-2010
Table 8: Tuberculosis Infection Market, Germany, Market Forecast ($m), 2010-2018
Table 9: Tuberculosis Infection Market, Italy, Revenue ($m), 2005-2010
Table 10: Tuberculosis Infection Market, Italy, Market Forecast ($m), 2010-2018
Table 11: Tuberculosis Infection Market, Spain, Revenue ($m), 2005-2010
Table 12: Tuberculosis Infection Market, Spain, Market Forecast ($m), 2010-2018
Table 13: Tuberculosis Infection Market, The UK, Revenue ($m), 2005-2010
Table 14: Tuberculosis Infection Market, The UK, Market Forecast ($m), 2010-2018
Table 15: Tuberculosis Infection, Japan, Revenue ($m), 2005-2010
Table 16: Tuberculosis Infection Market, Japan, Market Forecast ($m), 2010-2018
Table 17: Tuberculosis Market - Phase III Clinical Pipeline, 2010
Table 18: Tuberculosis Market - Phase II Clinical Pipeline, 2010
Table 19: Tuberculosis Market - Phase I Clinical Pipeline, 2010
Table 20: Tuberculosis Market - Preclinical Pipeline, 2010
Table 21: Tuberculosis Market - Discovery Pipeline, 2010
Table 22: Tuberculosis Infection - Most Promising Drugs Under Clinical Development, 2010
Table 23: Tuberculosis Market, Global, Clinical Trials, 2010
Table 24: Tuberculosis Market, Global, Clinical Trials by Phase, 2010
Table 25: Tuberculosis Market, Global, Clinical Trials by Status of Development, 2010
Table 26: Tuberculosis Market, Global, Prominent Sponsors, 2010
Table 27: Tuberculosis Market, Global, Sponsors, 2010
Table 28: Tuberculosis Market, Global, Companies by Phase, 2010
Table 29: Bayer - Tuberculosis Pipeline Products, 2010
Table 30: Sanofi - Tuberculosis Pipeline Products, 2010
Table 31: Pfizer - Tuberculosis Pipeline Products, 2010
Table 32: Novartis - Tuberculosis Pipeline Products, 2010
Table 33: TB Alliance - Tuberculosis Pipeline Products, 2010
Table 34: Aeras - Tuberculosis Pipeline Products, 2010
Table 35: Crucell - Tuberculosis Pipeline Products, 2010
Table 36: Tibotec - Tuberculosis Pipeline Products, 2010
Table 37: Tuberculosis therapeutics, Global, Deals, 2011

1.2 List of Figures
Figure 1: Sites of Extrapulmonary Tuberculosis
Figure 2: TB Incidence Rate - 2009
Figure 3: Pathophysiology of Tuberculosis
Figure 4: TB Treatment Algorithm
Figure 5: Tuberculosis Infection Market, Global, Revenues ($m), 2005-2010
Figure 6: Tuberculosis Infection Market, Global, Market Forecast ($m), 2010-2018
Figure 7: Tuberculosis Infection Market, The US, Revenue ($m), 2005-2010
Figure 8: Tuberculosis Infection Market, The US, Market Forecasts ($m), 2010-2018
Figure 9: Tuberculosis Infection Market, France, Revenue ($m), 2005-2010
Figure 10: Tuberculosis Infection Market, France, Market Forecast ($m), 2010-2018
Figure 11: Tuberculosis Infection Market, Germany, Revenue ($m), 2005-2010
Figure 12: Tuberculosis Infection Market, Germany, Market Forecast ($m), 2010-2018
Figure 13: Tuberculosis Infection Market, Italy, Revenue ($m), 2005-2010
Figure 14: Tuberculosis Infection Market, Italy, Market Forecast ($m), 2010-2018
Figure 15: Tuberculosis Infection Market, Spain, Revenue ($m), 2005-2010
Figure 16: Tuberculosis Infection Market, Spain, Market Forecast ($m), 2010-2018
Figure 17: Tuberculosis Infection Market, The UK, Revenue ($m), 2005-2010
Figure 18: Tuberculosis Infection Market, The UK, Market Forecast ($m), 2010-2018
Figure 19: Tuberculosis Infection Market, Japan, Revenue ($m), 2005-2010
Figure 20: Tuberculosis Infection Market, Japan, Market Forecast ($m), 2010-2018
Figure 21:Opportunity and Unmet Need in the Newly Diagnosed Tuberculosis Patients Therapeutic Market, 2010
Figure 22: Opportunity and Unmet Need in the MDR Tuberculosis Therapeutic Market, 2010
Figure 23: Opportunity and Unmet Need in the Tuberculosis Prophylactic Market, 2010
Figure 24: Strategic Competitor Assessment
Figure 25: Novel TB Drugs MOA Currently Under Development
Figure 26: Tuberculosis Infection Market - Clinical Pipeline by Mechanism of Action, 2010
Figure 27: Technology Trends Analytic Framework, 2010
Figure 28: Technology Trends Analytic Framework - Description, 2010
Figure 29: Tuberculosis - Clinical Pipeline by Phases of Development, 2010
Figure 30: Tuberculosis Market, Global, Clinical Trials by Country, 2010
Figure 31: Tuberculosis Market, Global, Clinical Trials by Phase, 2010
Figure 32: Tuberculosis Market, Global, Clinical Trials by Stage of Development, 2010
Figure 33: Tuberculosis Market, Global, Prominent Sponsors, 2010
Figure 34: Tuberculosis Market, Global, Overall Sponsors, 2010
Figure 35: Tuberculosis Market, Global, Companies by Phase, 2010
Figure 36: Tuberculosis Market, Drivers and Restraints, 2010
Figure 37: Implications for Future Market Competition in the Tuberculosis Drugs Market, 2010
Figure 38: Tuberculosis Market - Clinical Pipeline by Company, 2010
Figure 39: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Tuberculosis Infection - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Tuberculosis (TB) infection market. The report identifies the key trends shaping and driving the market. It also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global TB infection sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The Tuberculosis Infection Market is Forecast to Decline Until 2018

The global Tuberculosis (TB) infection market was worth $38.3m in 2010. It is expected to decline at a Compound Annual Growth Rate (CAGR) of 4.5% during the next eight years to reach $26.6m by 2018. The TB drugs market has been well served by antimycobacterial agents and antibiotics since the 1960s. Cure rates have been improved with the conventional Directly Observed Therapy (DOTS). Multi-Drug Resistant Tuberculosis (MDR-TB) was a consequence of patient non-compliance and the long duration of therapy. Companies are actively developing products for the prophylaxis and cure of TB with shorter treatment durations. Two not-for-profit organizations – TB Alliance and the Aeras Global TB Vaccine Foundation – partnered with pharmaceutical players to develop novel therapies and vaccines that can provide better patient compliance and prevention against TB. However, the global TB drugs market is likely to decline as no launches are expected until 2018. The number of prevalent and reported TB cases has also reduced due to increased access to the DOTS and DOTS-PLUS programs in developed countries.

Tuberculosis Infection Global, Revenue and Market Forecast ($m), 2005–2018

Source: GlobalData, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), GlobalData Epidemiology-Based Market Forecasting Model

Bayer
Sanofi
Pfizer 69
Novartis
TB Alliance, the US
Aeras (Aeras Global TB Vaccine Foundation), the US
Crucell, the Netherlands
Tibotec BVBA, Belgium